Shuaixiang Zhou

1.1k citations

24 papers · 725 indexed · h-index 14

Pharmacology top 10%
- Microbial Natural Products and Biosynthesis 4
Immunology
- Immunotherapy and Immune Responses 3
Oncology
- Cancer Immunotherapy and Biomarkers 5
- CAR-T cell therapy research 4
Biotechnology top 10%
Molecular Biology
- Photosynthetic Processes and Mechanisms 4
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 4
- Radiopharmaceutical Chemistry and Applications 3
Toxicology
- Bioactive Compounds and Antitumor Agents 2

Co-authors: Meizhong Luo Wen Liu Bingliang Chen Robert D. Willows Zhihai Wu Weiwei Wu Haiqing Ni Junjian Liu
Cited by: Pharmacology Immunology Oncology
Journals: Journal of the American Chemical Society (2 papers)Journal of Biological Chemistry (1 paper)PLANT PHYSIOLOGY (1 paper)
Partner nations: China Australia United States

In The Last Decade

Shuaixiang Zhou

22 papers receiving 717 citations

Peers

Countries citing papers authored by Shuaixiang Zhou

Since Specialization

Citations

This map shows the geographic impact of Shuaixiang Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuaixiang Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuaixiang Zhou more than expected).

Fields of papers citing papers by Shuaixiang Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuaixiang Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuaixiang Zhou. The network helps show where Shuaixiang Zhou may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shuaixiang Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shuaixiang Zhou Line = papers co-authored together Shuaixiang Zhou links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism Molecular Cancer Therapeutics ·Huan Zhang,Fufan He,Lei Cao,Haiqing Ni,Ninghuan Li,Yang Liu,Min Wu,Liu Ya,Bing Wu,Li Li,Zhihai Wu,Xiang Ling,Shuaixiang Zhou,Yiming Li,Shuxuan Deng,Weiwei Wu,Qian Chu	2025	0
2	Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models Cancer Immunology Immunotherapy ·Hongyu Xue,Zhimin Zhang,Li Li,Chenjuan Zhu,Keke Fei,Huijun Sha,Zhihai Wu,Xiaomin Lin,Feifei Wang,Shuaixiang Zhou,Xiya Deng,Yiming Li,Bingliang Chen,Yao Xiong,Kai Chen	2024	2
3	Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors Cancer Research ·Jian Guan,Shuaixiang Zhou,Weiwei Wu,Tianyu Zhu,Lei Cao,Ming Hai Wu,Ninghuan Li,Fenggen Fu,Zhengguan Liao,Shuming Lin,Zeyu Liu,Mengjia Zhu,Nana Luo,Ying Zhang,Tiong Sun Chia,Bingliang Chen,Kevin He	2024	2
4	IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma Cancer Letters ·Keke Fei,Haiqing Ni,Mengjia Zhu,Zhihui Kuang,Min Wu,Zhihai Wu,Fangfang Wang,Shuaixiang Zhou,Jing Hua,Weiwei Wu,Dongdong Wu,Dongmei Bai,Bingliang Chen	2022	2
5	Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy International Journal of Biological Macromolecules ·Ying Zhou,Haoran Shen,Min Wu,Jie Wang,Zhihai Wu,Fenggen Fu,Yang Liu,Jia Lü,Yao Ying,Nana Luo,Shuaixiang Zhou,Keai Sinn Tan,Bingliang Chen,Dongfang Wang	2022	6
6	Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity Cancer Immunology Immunotherapy ·Yan Wang,Haiqing Ni,Shuaixiang Zhou,Kaijie He,Yarong Gao,Weiwei Wu,Min Wu,Zhihai Wu,Xuan Qiu,Ying Zhou,Bingliang Chen,Donghui Pan,Chenrong Huang,Mingzhu Li,Yicong Bian,Min Yang,Liyan Miao,Junjian Liu	2020	87
7	IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis International Immunopharmacology ·Li Li,Zhihai Wu,Min Wu,Xuan Qiu,Yue Wu,Zhihui Kuang,Li Wang,Sun Ta,Yang Liu,Yi Shuai,Jing Hua,Shuaixiang Zhou,Bingliang Chen,Dongdong Wu,Weiwei Wu,Junjian Liu	2020	9
8	Abstract 3270: Dual blockade of PD-L1 and LAG-3 using a bispecific antibody improves anti-tumor immunity Cancer Research ·Haiqing Ni,Yajing Qiu,Jing Hua,Pan Zhang,Bingliang Chen,Zhihai Wu,Shuaixiang Zhou,Dechao Yu,Junjian Liu	2020	1
9	Development and characterization of a novel anti-OX40 antibody for potent immune activation Cancer Immunology Immunotherapy ·Zhihui Kuang,Jing Hua,Zhihai Wu,Jie Wang,Yiming Li,Haiqing Ni,Pan Zhang,Weiwei Wu,Min Wu,Shuaixiang Zhou,Xuan Qiu,Dongdong Wu,Bianka Prinz,Hemanta Baruah,Bingliang Chen,Michael Yu,Junjian Liu	2020	20
10	Radical S-Adenosylmethionine Protein NosN Forms the Side Ring System of Nosiheptide by Functionalizing the Polythiazolyl Peptide S-Conjugated Indolic Moiety Organic Letters ·Yanping Qiu,Yanan Du,Shoufeng Wang,Shuaixiang Zhou,Yinlong Guo,Wen Liu	2019	16
11	Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit mAbs ·Jie Wang,Keke Fei,Jing Hua,Zhihai Wu,Weiwei Wu,Shuaixiang Zhou,Haiqing Ni,Bingliang Chen,Yan Xiong,Yanpeng Liu,Bo Peng,Dechao Yu,Haiping Jiang,Junjian Liu	2019	97
12	Thiolation Protein-Based Transfer of Indolyl to a Ribosomally Synthesized Polythiazolyl Peptide Intermediate during the Biosynthesis of the Side-Ring System of Nosiheptide Journal of the American Chemical Society ·Yanping Qiu,Yanan Du,Fang Zhang,Rijing Liao,Shuaixiang Zhou,Chao Peng,Yinlong Guo,Wen Liu	2017	19
13	1-N-histidine phosphorylation of ChlD by the AAA+ ChlI2 stimulates magnesium chelatase activity in chlorophyll synthesis Biochemical Journal ·Artur Sawicki,Shuaixiang Zhou,Kathrin Kwiatkowski,Meizhong Luo,Robert D. Willows	2017	14
14	Processing 2-Methyl-l-Tryptophan through Tandem Transamination and Selective Oxygenation Initiates Indole Ring Expansion in the Biosynthesis of Thiostrepton Journal of the American Chemical Society ·Zhi Lin,Jia Ji,Shuaixiang Zhou,Fang Zhang,Jiequn Wu,Yinlong Guo,Wen Liu	2017	28
15	GUN4-Protoporphyrin IX Is a Singlet Oxygen Generator with Consequences for Plastid Retrograde Signaling Journal of Biological Chemistry ·Shabnam Tarahi Tabrizi,Artur Sawicki,Shuaixiang Zhou,Meizhong Luo,Robert D. Willows	2016	35
16	An enzymatic [4+2] cyclization cascade creates the pentacyclic core of pyrroindomycins Nature Chemical Biology ·Zhenhua Tian,Peng Sun,Yan Yan,Zhuhua Wu,Qingfei Zheng,Shuaixiang Zhou,Hua Zhang,Futao Yu,Xinying Jia,Dandan Chen,Attila Mándi,Tibor Kurtán,Wen Liu	2015	121
17	Inducing the oxidative stress response in Escherichia coli improves the quality of a recombinant protein: Magnesium chelatase ChlH Protein Expression and Purification ·André H. Müller,Artur Sawicki,Shuaixiang Zhou,Shabnam Tarahi Tabrizi,Meizhong Luo,Mats Hansson,Robert D. Willows	2014	8
18	Opportunities and challenges from current investigations into the biosynthetic logic of nosiheptide-represented thiopeptide antibiotics Current Opinion in Chemical Biology ·Shoufeng Wang,Shuaixiang Zhou,Wen Liu	2013	38
19	C‐terminal residues of Oryza sativa GUN4 are required for the activation of the ChlH subunit of magnesium chelatase in chlorophyll synthesis FEBS Letters ·Shuaixiang Zhou,Artur Sawicki,Robert D. Willows,Meizhong Luo	2012	40
20	Thioredoxin Redox Regulates ATPase Activity of Magnesium Chelatase CHLI Subunit and Modulates Redox-Mediated Signaling in Tetrapyrrole Biosynthesis and Homeostasis of Reactive Oxygen Species in Pea Plants PLANT PHYSIOLOGY ·Tao Luo,Tingting Fan,Yinan Liu,Maxi Rothbart,Jing Yu,Shuaixiang Zhou,Bernhard Grimm,Meizhong Luo	2012	78

About Shuaixiang Zhou

Shuaixiang Zhou is a scholar working on Toxicology, Immunology and Biotechnology, having authored 24 papers that have together received 725 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Microbial Natural Products and Biosynthesis (4 papers), CAR-T cell therapy research (4 papers), Photosynthetic Processes and Mechanisms (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Immunotherapy and Immune Responses (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). The work is most often cited by research in Pharmacology (156 citations), Immunology (176 citations) and Oncology (217 citations). Shuaixiang Zhou has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Meizhong Luo, Wen Liu, Bingliang Chen, Robert D. Willows, Zhihai Wu, Weiwei Wu, Haiqing Ni, Junjian Liu, Shoufeng Wang and Jing Hua. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and PLANT PHYSIOLOGY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact